ClinicalTrials.gg
CompletedNCT06140628Updated Aug 16, 2024

A 28-day Clinical Study on Facial Skin Rejuvenation

An interventional study of Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002® and Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002® in Wrinkle, Skin Laxity and Skin Manifestations, sponsored by Botanee Group Co., Ltd.. Completed at 1 site in China. Open to female participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Botanee Group Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
Female
01

Study summary

This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.

Read the detailed description

The main expectation it aims to answer are:

  • After the 4-week continuous use of the test skin product with MLYAAT-1002®, the skin aging problem is significantly improved compared with it of controlled product.
  • After the single use of the test skin product with MLYAAT-1002®, the instant skin irritation after the Fotona4D Pro® treatment ( a nonablative fractional laser treatment for facial skin rejuvenation) is significantly lower compared with it of controlled product.
  • After the 4-week continuous use of the test skin product with MLYAAT-1002®, the skin TEWL (transepidermal water loss) is significantly recovered from the Fotona4D Pro® treatment compared with it of controlled product. And the skin TEWL after the 4-week continuous use of test product is improved or not significantly worse than it before the Fotona4D Pro® treatment.
  • After the 4-week continuous use of the test skin product with MLYAAT-1002®, no skin irritation symptom is worsen compared to it after the Fotona4D Pro® treatment.
02

Conditions studied

  • Wrinkle
  • Skin Laxity
  • Skin Manifestations
  • Skin

Browse trials for

03

In context

Skin Manifestations

29 studies on the registry are indexed under Skin Manifestations; 5 are open to participants now.

This study's enrollment of 37 is below the median of 75 across 23 interventional studies indexed under Skin Manifestations.

Browse Skin Manifestations studies →

Lead sponsor

Botanee Group Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females aged 30-50
  • no history of cosmetic allergies
  • according to SKIN AGING ATLAS 2(Asian Type), the scores of under-eye wrinkles, pore appearance, forehead wrinkles are all > 2
  • non-sensitive skin
  • acceptable for split-face use of products for 28 days
  • no using history of antibiotic in the past three months
  • written and portrait right consent were obtained from all participants before study entry

Exclusion criteria

Exclusion Criteria:

  • subjects with known allergies or sensitivities to the ingredients in any of the study products
  • anyone who is pregnant, nursing an infant, or planning a pregnancy during the study
  • any symptoms of facial flushing, erythema, papules, desquamation, or edema as evaluated by a physician prior to initial screening or Fotona4D Pro treatment
  • unhealed skin lesions
  • participated in any other clinical trial within one month
  • received facial skin treatments including but not limited to lasers, chemical peels, dermal fillers within one year
  • taken/injected anti-allergy medication in the past one month
  • other medical reasons that could affect the test results
  • participants in other clinical trials at the same time
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    Formulation containing MLYAAT-1002® Composition

    After the Fotana4D Pro® treatment, daily use of the formulation for 28 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.

    Combination Product: Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®

  • Placebo comparator
    Blank formulation without MLYAAT-1002® Composition

    After the Fotana4D Pro® treatment, daily use of the blank formulation for 28 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.

    Combination Product: Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®

Interventions

  • Combination productFotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®

    Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.

  • Combination productFotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®

    Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.

06

What researchers measure

Primary outcomes

  1. changes in individual typology angle (ITA°) of facial skin

    capturing facial images by VISIA-7 (CANFIELD, America) and calculating the ITA

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  2. changes in elasticity of facial skin (R2)

    measuring gross elasticity (R2) by Cutometer® MPA580 (Courage\&Khazaka, Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  3. changes in elasticity of facial skin (F4)

    measuring firmness (F4) by Cutometer® MPA580 (Courage\&Khazaka, Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  4. changes in facial skin topography (SEsm)

    evaluating skin smoothness (SEsm) using VisioScan VC20(Courage\&Khazaka,Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  5. changes in facial skin topography (SEw)

    evaluating wrinkles (SEw) using VisioScan VC20(Courage\&Khazaka,Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  6. changes in fine line depth of facial skin

    evaluating peri orbital fine lines by Primos(CANFIELD, America)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  7. changes in wrinkle depth of facial skin

    evaluating crow's feet wrinkles by Primos(CANFIELD, America)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  8. changes in skin thickness of facial skin

    measuring skin thickness in µm by Ultrascan UC22(Courage\&Khazaka,Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

  9. changes in skin density of facial skin

    measuring skin density (ultrasound density in % ) by Ultrascan UC22(Courage\&Khazaka,Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

Secondary outcomes

  1. changes in transepidermal water loss (TEWL,in g/m2/h) of facial skin

    measuring the loss of water that passes from inside a body through the epidermis to the surrounding atmosphere by Tewameter® MPA580 (Courage\&Khazaka,Germany)

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28

07

Study locations

1 site
  • Shanghai China-norm Quality Technical Service Co., Ltd.
    Shanghai, Shanghai 200072, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2023, 1 month.

Of 14 interventional studies with no phase under Skin Manifestations, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 20, 2023
StartActual
Sep 24, 2023
Primary completionActual
Nov 7, 2023
CompletionActual
Apr 8, 2024
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06140628
Lead sponsor
Botanee Group Co., Ltd.
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Sep 24, 2023
Primary completion
Nov 7, 2023
Completion
Apr 8, 2024
Last update
Aug 16, 2024

Study contacts

Xiaoke Xu, Dr
principal investigator · Shenzhen Xiaoke BeauCare Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion